The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: An Open-label Extension Study of PSMA ADC 2301 in mCRPC
Official Title: An Open-label Treatment Extension of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Study ID: NCT02020135
Brief Summary: PSMA ADC 2301EXT is an open-label study to further assess the anti-tumor activity as measured by radiographic imaging and biomarkers, safety and tolerability of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in subjects with mCRPC. Subjects who have participated in the PSMA ADC 2301 study and who, in the opinion of the Principal Investigator are likely to benefit from continued treatment with PSMA ADC are eligible for the PSMA ADC 2301 extension study. Subjects who are benefiting from treatment may be able to receive up to an additional eight to sixteen doses (every 3 weeks) of PSMA ADC.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
, Tucson, Arizona, United States
, New Orleans, Louisiana, United States
, Baltimore, Maryland, United States
, Las Vegas, Nevada, United States
, Stony Brook, New York, United States
, Myrtle Beach, South Carolina, United States
Name: Vivien Wong, PhD
Affiliation: Progenics Pharmaceuticals, Inc.
Role: STUDY_DIRECTOR